A drug developed by National Taiwan University Hospital (NTUH) has been approved for sale in the European Union for the treatment of aromatic-L-amino acid decarboxylase (AADC) deficiency, a rare life-threatening disorder that affects children, the hospital said Friday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Bus company chairman resigns after surgeon run over and killed
07/20/2025 05:06 PM - Sports
Taiwan's women's table tennis team clinch Universiade bronze
07/20/2025 04:23 PM - Politics
U.S. House passes US$500 million in Taiwan aid
07/20/2025 03:42 PM - Society
Taiwan headline news
07/20/2025 03:42 PM - Culture
Prague Zoo celebrates as Taiwan-linked Formosan Pangolin cub turns 1
07/20/2025 02:27 PM